Prepared by R.R. Donnelley Financial -- EX-10.16(d)




 Exhibit 10.16(d) 

 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 AMENDMENT #3 TO TASK ORDER #13 

COHERUS Project Number: CHS0214-02 

MEDPACE Project Number: ETA302 

This Amendment #3 (“Amendment #3”) to Task Order #13 effective as of 18 October 2013 (“Task Order”), is by and
between Coherus Bioscience, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200 Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of business at 5375
Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #3 shall be effective 30 May 2014. 
 WITNESSETH: 

WHEREAS, the Parties have entered into Task Order pursuant and subject to the terms of the Master Service Agreement dated 23 January
2012, (the “Agreement”); and 
 WHEREAS, the Parties desire to amend Task Order in connection with a Phase 3, A Double-Blind,
Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 DP Versus Enbrel® in Subjects with Rheumatoid Arthritis and Inadequate Response to Treatment
with Methotrexate to increase the MRL and [***] fees included in the Budget. 
 NOW, THEREFORE, in consideration of the mutual covenants
contained herein, the Parties hereby agree as follows to the revised Scope of Work: 
  

	 	1.	Appendix F: MRL and [***] Services and Budget attached to Task Order #13 is hereby amended by Appendix F attached to this Amendment #3. 


 

	 	2.	The MRL and [***] Fees line item included under the Pass-through Expenses category in Appendix C: Services and Budget is hereby increased from [***] to [***]. (“Increase”). 


 

	 	3.	As a result of the Increase in the Budget, Appendix D: Payment Schedule, attached to the Task Order is hereby amended to include the following: 


A total of [***] is due upon execution of Amendment #3. The remainder of the Increase will be paid in accordance with the terms of Appendix D:
Payment Schedule, attached to the Task Order. 
 The total amount payable by Sponsor to Medpace under this Amendment #3 for Medpace Direct Fees,
Pass-through Expenses, and Pre-funded Expenses shall not exceed the amount of [***] without prior written consent of both parties. The total value of Task Order and all subsequent amendments is now [***]. 

  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 1












									
	 	  	Direct Fees	  	Pass Through Costs	  	Pre-funded Expenses	  	TOTAL
	 Task Order #13
	  	[***]	  	[***]	  	[***]	  	[***]
	 Amendment #1
	  	[***]	  	[***]	  	[***]	  	[***]
	 Amendment #2
	  	[***]	  	[***]	  	[***]	  	[***]
	 Amendment #3
	  	[***]	  	[***]	  	[***]	  	[***]
	 TOTAL
	  	[***]	  	[***]	  	[***]	  	[***]

 All other provisions of the Agreement and Task Order shall remain unchanged and in effect. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Amendment #3 to Task Order in their official capacities which shall be effective on the day and year
listed above. 
  

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne
		
	By:	 	John Wynne
		 	    (Print Name)
		
	Title:	 	Vice President
		 	Commercial Operations

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear
		
	By:	 	Dennis M. Lanfear
		 	    (Print Name)
		
	Title:	 	President & CEO 5/30/14


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 2



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











			
	 Sponsor: Coherus Biosciences
 Protocol:
CHS-0214-02
	  	 30-May-14


  

					
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 Total Medpace Reference Laboratories Fees
	  	 	[***]	  


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 3



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 Medpace Reference Laboratories Fee Estimate 

 

																																							
	Sponsor: Coherus Biosciences	  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
	Protocol: CHS-0214-02	  		  		  		  		  		  		  	[***]	 		  		  		  		  		  		  		  	
																				
		 		 		  		  		  		  		  		  		  		  		  	[***]	 		  		  		  		  		  		  		  	
	 	 	 	 	 	  	Unit Cost	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	Total
Number
of Units	  	Cost	  	Subtotal
	 Laboratory Tests
	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	[***]
		 		 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  	[***]	  	[***]	  		  		  		  	[***]	  		  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  	[***]	  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
	 Laboratory Support Services
	  		  		  		  		  		 		  		  		  		  		  		  		  	[***]
	 [***]
	 		 		  		  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 	[***]	 		  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 	[***]	 		  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
	 [***]
	 		 		  		  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
	 [***]
	 		 		  		  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  		  	[***]	  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  	[***]	  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  	[***]	  		  		  		  	[***]	  		  	[***]	 		  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
		 		 	[***]	  	[***]	  		  		  		  		  		  		  		  		 		  		  		  		  		  		  		  	
	Total Medpace Reference Laboratory Fees	  		  		  		  		 		  		  		  		  		  		  		  	[***]


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 4

	
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.











 Medpace Reference Laboratories Fee Estimate 

 

																																					
	Sponsor: Coherus Biosciences	 		 		 		 		 		 		 		 		 		 		 		 		 		 	
	Protocol: CHS-0214-02	 		 		 		 		 		 	[***]	 		 		 		 		 		 		 		 	
																			
		  		  		 		 		 		 		 		 		 		 	[***]	 		 		 		 		 		 		 		 	
	 	  	 	  	Unit Cost	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total
Number
of Units	 	Cost	 	Subtotal
	Laboratory Tests	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]
		  	[***]	  	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]	 	
		  	[***]	  	[***]	 	[***]	 	[***]	 		 	[***]	 		 	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	
		  	[***]	  	[***]	 	[***]	 	[***]	 		 	[***]	 		 	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	
		  	[***]	  		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		  	[***]	  	[***]	 	[***]	 	[***]	 		 		 		 	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	
		  	[***]	  	[***]	 	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
	Laboratory Support Services	 		 		 		 		 		 		 		 		 		 		 		 	[***]
	 [***]
	  		  		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
	 [***]
	  		  		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		  	[***]	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
	 [***]
	  		  		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		  	[***]	  	[***]	 		 	[***]	 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 	[***]	 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 	[***]	 		 		 		 	[***]	 		 	[***]	 		 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
		  	[***]	  	[***]	 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
	 Total Medpace Reference Laboratory Fees
	 		 		 		 		 		 		 		 		 		 		 		 	[***]


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 5

	
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.











 Medpace Reference Laboratories Fee Estimate 

 

																																									
	Sponsor: Coherus Biosciences	  		  		  		  		  		  	 	[	***] 	 		  		  		  		  		  		  		  			
	Protocol: CHS-0214-02	  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
																			
		  		  		  		  		  		  		  		  		  		  	 	[	***] 	 		  		  		  		  		  		  		  			
	 	  	 	  	Unit Cost	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	 	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	Total
Number
of Units	  	Cost	  	Subtotal	 
	Laboratory Tests	  		  		  		  		  				 		  		  		  		  		  		  		  	 	[***]	  
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]	  	 	[***]	  	 	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  			
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  			
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  			
		  	[***]	  	[***]	  	[***]	  	[***]	  		  		  		  	[***]	  		  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  			
		  	[***]	  	[***]	  	[***]	  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
	Laboratory Support Services	  		  		  		  		  		  				 		  		  		  		  		  		  		  	 	[***]	  
	[***]	  		  		  		  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]	  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
	[***]	  		  		  		  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
	[***]	  		  		  		  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
		  	[***]	  	[***]	  		  	[***]	  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  	[***]	  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  	[***]	  		  		  		  	[***]	  		  	 	[***]	  	 		  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 	[***]	  	 	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
		  	[***]	  	[***]	  		  		  		  		  		  		  		  				 		  		  		  		  		  		  		  			
	Total Medpace Reference Laboratory Fees	  		  				 		  		  		  		  		  		  		  	 	[***]	  


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 6

	
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.











 Medpace Reference Laboratories Pass Through Estimate 

 

									
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-02
	  	Average
Cost per Unit	 	Estimated
Number of
Units	 	Total Cost	 	Subtotal
	 Pass Through Estimates
	  		 		 		 	[***]
	 [***]
	  		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	
	 [***]
	  	[***]	 		 	[***]	 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	
	 [***]
	  		 		 	[***]	 	
	 Total Estimated Medpace Reference Laboratory Pass-Through Fees
	  		 		 		 	[***]


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 7



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 Transportation Costs 
  

																											
	 Country
	  	Sites	  	Number
Screened	  	Number
Randomized	  	Number
Ambient /
Refrigerate
shipments	  	Number
Frozen
Shipments	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Total
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  	[***]	  		  		  		  		  		  	[***]	  	[***]	  		  	
		  		  		  		  		  		  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 8



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











			
	Costs	  	1 Resupplies per site        

  

																											
	 Sites
	  	Number
Screened	  	Number
Randomized	  	Number
Ambient /
Refrigerate
shipments	  	Number
Frozen
Shipments	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  	[***]	  		  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	[***]


  

			
	



	  	 Amendment #3 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 9



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.